Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy

PURPOSE: Bispecific antibodies (BsAbs) have emerged as a leading drug class for cancer therapy and are becoming increasingly of interest for therapeutic applications. As of April 2020, over 123 BsAbs are under clinical evaluation for use in oncology (including the two marketed BsAbs Blinatumomab and...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shuyu, van Duijnhoven, Sander M. J., Sijts, Alice J. A. M., van Elsas, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679314/
https://www.ncbi.nlm.nih.gov/pubmed/32989604
http://dx.doi.org/10.1007/s00432-020-03404-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679314/
https://www.ncbi.nlm.nih.gov/pubmed/32989604
http://dx.doi.org/10.1007/s00432-020-03404-6

Ejemplares similares